Online inquiry

IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3581MR)

This product GTTS-WQ3581MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LYPD3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_014400.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27076
UniProt ID O95274
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3581MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9400MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ4870MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ11495MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ14130MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA aPCSK927
GTTS-WQ9876MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ13722MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ1762MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ2887MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG-761
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW